AVX-470
Phase 1- Indications
- Ulcerative colitis
Company intelligence / Profile preview
Avaxia Biologics
Lexington, Massachusetts, United Statesavaxiabiologics.com ↗
- Ownership
- Private
- Employees
- ~14
- Development stage
- Phase 1
01
Overview
AVX‑470, an orally administered bovine polyclonal anti-TNF antibody for ulcerative colitis, demonstrated safety and proof-of-mechanism in a Phase 1b trial. The product received FDA Orphan Drug Designation for pediatric ulcerative colitis. The company also developed a recombinant platform (“Avaximabs”) to rapidly generate gut-stable antibodies against various targets. Additional preclinical programs targeted other GI diseases[1][5][8].
- Therapeutic areas
- GastroenterologyEndocrinology
- Modalities
- Polyclonal antibodiesRecombinant monoclonal antibodies
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Government contracts/BARDA support; pharma interest but no major deals disclosed.
Beyond the preview
Go deeper on Avaxia Biologics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Avaxia Biologics.